Matinas BioPharma
MTNB
56 hedge funds and large institutions have $20.3M invested in Matinas BioPharma in 2022 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 10 increasing their positions, 9 reducing their positions, and 17 closing their positions.
11% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 9
0.02% less ownership
Funds ownership: 0.25% → 0.23% (-0.02%)
15% less funds holding
Funds holding: 66 → 56 (-10)
26% less capital invested
Capital invested by funds: $27.4M → $20.3M (-$7.09M)
59% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAG
Private Advisor Group
Morristown,
New Jersey
|
+$65.9K |
| 2 |
State Street
Boston,
Massachusetts
|
+$38.9K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$32.3K |
| 4 |
BlackRock
New York
|
+$21.8K |
| 5 |
Jane Street
New York
|
+$11.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Courage Capital Management
Nashville,
Tennessee
|
-$662K |
| 2 |
Truist Financial
Charlotte,
North Carolina
|
-$207K |
| 3 |
SWM
Spire Wealth Management
Mclean,
Virginia
|
-$163K |
| 4 |
DA
DCF Advisers
Greenwich,
Connecticut
|
-$156K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$119K |
MTNB Hedge Fund Activity: Q1 2022 in Review
56 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Matinas BioPharma (MTNB) for Q1 2022, worth a combined $20.3M — down 26% from $27.4M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of MTNB and 7 opened new positions — a net loss of 10 holders — while 9 trimmed existing stakes and 10 added.
The largest buyer was Private Advisor Group, adding an estimated $65.9K. The largest seller was Courage Capital Management, cutting an estimated $662K.
- 56 institutional investors held Matinas BioPharma (MTNB) as of Q1 2022, down from 66 in Q4 2021.
- Funds reported $20.3M of Matinas BioPharma stock for Q1 2022, down 26% quarter-over-quarter.
- 7 funds opened new Matinas BioPharma positions in Q1 2022 and 17 closed out, a net change of -10 holders.
- The largest Matinas BioPharma buyer in Q1 2022 was Private Advisor Group, an estimated $65.9K added.
- The largest Matinas BioPharma seller in Q1 2022 was Courage Capital Management, an estimated $662K sold.
Based on aggregated 13F filings for Q1 2022.